---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-048558"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-04-22T23:59:59+00:00"
generated_at: "2026-06-26T05:15:35.570756+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CMS expands Tyvaso coverage to include PH-ILD; effective June 5, 2022

## Summary
- CMS updated Local Coverage Determination for Tyvaso (treprostinil) to include pulmonary hypertension associated with interstitial lung disease.
- Coverage effective June 5, 2022, after a 45-day notice period as announced April 21, 2022.
- Tyvaso is a treprostinil inhalation solution marketed by United Therapeutics for pulmonary hypertension.

## SEC filing metadata
- accession: 0001104659-22-048558
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-04-22T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/0001104659-22-048558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465922048558/tm2213312d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-048558
- JSON: https://secwatch.observer/filing/0001104659-22-048558.json
- Plain text: https://secwatch.observer/filing/0001104659-22-048558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.